Jump to content

Methylenedioxyallylamphetamine

From Wikipedia, the free encyclopedia
Methylenedioxyallylamphetamine
Names
Preferred IUPAC name
N-[1-(2H-1,3-Benzodioxol-5-yl)propan-2-yl]prop-2-en-1-amine
Identifiers
3D model (JSmol)
ChemSpider
UNII
  • InChI=1S/C13H17NO2/c1-3-6-14-10(2)7-11-4-5-12-13(8-11)16-9-15-12/h3-5,8,10,14H,1,6-7,9H2,2H3 ☒N
    Key: BMKCDDFQEGYEJC-UHFFFAOYSA-N ☒N
  • InChI=1/C13H17NO2/c1-3-6-14-10(2)7-11-4-5-12-13(8-11)16-9-15-12/h3-5,8,10,14H,1,6-7,9H2,2H3
    Key: BMKCDDFQEGYEJC-UHFFFAOYAO
  • C1=C2C(=CC=C1CC(C)NCC=C)OCO2
Properties
C13H17NO2
Molar mass 219.284 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
☒N verify (what is checkY☒N ?)

Methylenedioxyallylamphetamine (MDAL or 3,4-methylenedioxy-N-allylamphetamine) is a lesser-known psychedelic drug. It is also the N-allyl derivative of 3,4-methylenedioxyamphetamine (MDA). MDAL was first synthesized by Alexander Shulgin. In his book PiHKAL, the minimum dosage is listed as 180 mg, and the duration unknown.[1] MDAL produces few to no effects on its own, but may enhance the effects of LSD. Very little data exists about the pharmacological properties, metabolism, and toxicity of MDAL.

Legality

[edit]

United Kingdom

[edit]

This substance is a Class A drug in the Drugs controlled by the UK Misuse of Drugs Act.[2]

See also

[edit]

References

[edit]
  1. ^ MDAL entry in PiHKAL
  2. ^ "UK Misuse of Drugs act 2001 Amendment summary". Isomer Design. Archived from the original on 22 October 2017. Retrieved 12 March 2014.